Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

462

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

March 31, 2014

Study Completion Date

September 14, 2023

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

OTHER

No treatment

Trial Locations (72)

Unknown

Queen Elizabeth Hospital, Adelaide

Royal Adelaide Hospital, Adelaide

Ashford Cancer Centre, Black Forest

Boxhill Hospital, Box Hill

Royal Brisbane and Women's Hospital, Brisbane

Canberra Hospital, Canberra

Concord Repatriation General Hospital, Concord

Frankston Hospital, Frankston

Fremantle Hospital, Fremantle

Gosford Hospital, Gosford

Royal Hobart Hospital, Hobart

Nepean Hospital, Kingswood

Lismore Base Hospital, Lismore

Liverpool Hospital, Liverpool

Alfred Hospital, Melbourne

Austin Health, Melbourne

Peter MacCallum Cancer Centre, Melbourne

St Vincent's Hospital, Melbourne

Mater Misericordiae Hospital, Newcastle

Royal Perth Hospital, Perth

Royal North Shore Hospital, St Leonards

St Vincent's Hospital, Sydney

Westmead Hospital, Westmead

Murray Valley Private Hospital, Wodonga

Wollongong Hospital, Wollongong

Princess Alexandra Hospital, Woolloongabba

Auckland Hospital, Auckland

Middlemore Hospital, Auckland

Christchurch Hospital, Christchurch

North Shore Hospital, Westlake

Royal Alexandra Hospital, Paisley

B9 5SS

Birmingham Heartlands Hospital, Birmingham

FY3 8NR

Blackpool Victoria Hospital, Blackpool

IP33 2QZ

West Suffolk Hospital, Bury St Edmunds

CT1 3NG

Kent and Canterbury Hospital, Canterbury

SM5 1AA

St. Helier Hospital, Carshalton

EX2 5DW

Royal Devon and Exeter Hospital, Exeter

NE9 6SX

Queen Elizabeth Hospital, Gateshead

ME7 5NY

Medway Maritime Hospital, Gillingham

HP2 4AD

Hemel Hempstead General, Hemel Hempstead

HU3 2KZ

Hull Royal Infirmary, Hull

TW7 6AF

West Middlesex University Hospital, Isleworth

NNI6 8UZ

Kettering General Hosptial, Kettering

DY11 6RJ

Kidderminster Hospital, Kidderminster

PE30 4ET

Queen Elizabeth Hospital, Kings Lynn

LE1 5WW

Leicester Royal Infirmary, Leicester

SW17 0QT

St. George's Hospital, London

ME16 9QQ

Maidstone Hospital, Maidstone

NE1 4LP

Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle upon Tyne

HA6 2RN

Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood

PR2 9HT

Rosemere Cancer Centre at Royal Preston Hospital, Preston

B98 7UB

Alexandra Healthcare NHS, Redditch

RM7 OBE

Oldchurch Hospital, Romford

TN2 4QJ

Pembury Hospital, Royal Tunbridge Wells

SO16 6YD

Southampton General Hospital, Southampton

ST16 3SA

Staffordshire General Hospital, Stafford

SM2 5PT

Royal Marsden - Surrey, Sutton

TQ2 7AA

Torbay Hospital, Torquay

TR1 3LJ

Royal Cornwall Hospital, Truro

BS23 4TQ

Weston General Hospital, Weston-super-Mare

WR5 1DD

Worcester Royal Hospital, Worcester

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

ML6 0JF

Monklands General Hospital, Airdrie

G75 8RG

Hairmyres Hospital, East Kilbride

EH4 2XU

Edinburgh Cancer Centre at Western General Hospital, Edinburgh

G51 4TF

Southern General Hospital, Glasgow

1V2 3UJ

Raigmore Hospital, Inverness

ML2 0DP

Wishaw General Hospital, Wishaw

CF14 2TL

Velindre Cancer Center at Velindre Hospital, Cardiff

CF47 9DT

Prince Charles Hospital, Merthyr Tydfil

LL 18 5UJ

Glan Clwyd Hospital, Rhyl

SA2 8QA

South West Wales Cancer Institute, Swansea

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Roche Pharma AG

INDUSTRY

lead

University College, London

OTHER

NCT00112931 - Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter